4194 Stock Overview
Holy Stone Healthcare Co., Ltd. develops therapeutics in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Holy Stone Healthcare Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$17.65 |
| 52 Week High | NT$42.64 |
| 52 Week Low | NT$15.85 |
| Beta | 1.41 |
| 1 Month Change | 3.82% |
| 3 Month Change | -7.15% |
| 1 Year Change | -56.66% |
| 3 Year Change | -21.38% |
| 5 Year Change | 16.06% |
| Change since IPO | -82.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4194 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0.9% | -0.7% | -1.6% |
| 1Y | -56.7% | -23.7% | 25.9% |
Return vs Industry: 4194 underperformed the TW Biotechs industry which returned -23.7% over the past year.
Return vs Market: 4194 underperformed the TW Market which returned 25.9% over the past year.
Price Volatility
| 4194 volatility | |
|---|---|
| 4194 Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4194 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4194's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Albert Wu | www.hshc.com.tw |
Holy Stone Healthcare Co., Ltd. develops therapeutics in Taiwan. It offers RenehaVis, a product designed to relive pain and stiffness of the knee joint; SportVis, a treatment to relive the pain and optimize the recovery of tendon and ligament injuries; TRUD, a treatment that allows mucosal tissue to heal naturally and reduces the symptoms of ulcerative colitis; and GAF, a treatment for anal mucosal lesions. The company is also developing IBD98-M, which is in Phase IIa clinical trials for the treatment of inflammatory bowel diseases; and CA102N to treat colorectal cancer.
Holy Stone Healthcare Co., Ltd. Fundamentals Summary
| 4194 fundamental statistics | |
|---|---|
| Market cap | NT$2.17b |
| Earnings (TTM) | -NT$289.37m |
| Revenue (TTM) | NT$236.89m |
9.2x
P/S Ratio-7.5x
P/E RatioIs 4194 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4194 income statement (TTM) | |
|---|---|
| Revenue | NT$236.89m |
| Cost of Revenue | NT$137.51m |
| Gross Profit | NT$99.38m |
| Other Expenses | NT$388.75m |
| Earnings | -NT$289.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.35 |
| Gross Margin | 41.95% |
| Net Profit Margin | -122.15% |
| Debt/Equity Ratio | 72.0% |
How did 4194 perform over the long term?
See historical performance and comparison